SG11202005526WA - Peptide immunogens of il-31 and formulations thereof for the treatment and/or prevention of atopic dermatitis - Google Patents
Peptide immunogens of il-31 and formulations thereof for the treatment and/or prevention of atopic dermatitisInfo
- Publication number
- SG11202005526WA SG11202005526WA SG11202005526WA SG11202005526WA SG11202005526WA SG 11202005526W A SG11202005526W A SG 11202005526WA SG 11202005526W A SG11202005526W A SG 11202005526WA SG 11202005526W A SG11202005526W A SG 11202005526WA SG 11202005526W A SG11202005526W A SG 11202005526WA
- Authority
- SG
- Singapore
- Prior art keywords
- formulations
- prevention
- treatment
- atopic dermatitis
- peptide immunogens
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6018—Lipids, e.g. in lipopeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- External Artificial Organs (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762597130P | 2017-12-11 | 2017-12-11 | |
| PCT/US2018/065025 WO2019118512A2 (en) | 2017-12-11 | 2018-12-11 | Peptide immunogens of il-31 and formulations thereof for the treatment and/or prevention of atopic dermatitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202005526WA true SG11202005526WA (en) | 2020-07-29 |
Family
ID=66820956
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202005526WA SG11202005526WA (en) | 2017-12-11 | 2018-12-11 | Peptide immunogens of il-31 and formulations thereof for the treatment and/or prevention of atopic dermatitis |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20210079054A1 (en) |
| EP (1) | EP3724218A2 (en) |
| JP (1) | JP7250032B2 (en) |
| KR (1) | KR20210009296A (en) |
| CN (1) | CN111448208B (en) |
| AU (1) | AU2018383708B2 (en) |
| BR (1) | BR112020011308A2 (en) |
| CA (1) | CA3085318A1 (en) |
| MX (1) | MX2020006105A (en) |
| SG (1) | SG11202005526WA (en) |
| TW (1) | TWI741241B (en) |
| WO (1) | WO2019118512A2 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018156180A1 (en) | 2017-02-24 | 2018-08-30 | Kindred Biosciences, Inc. | Anti-il31 antibodies for veterinary use |
| BR112020017715A2 (en) | 2018-03-16 | 2020-12-29 | Zoetis Services Llc | PEPTIDE VACCINES AGAINST INTERLEUCIN-31 |
| CN114555121A (en) * | 2019-08-29 | 2022-05-27 | 金德雷德生物科学股份有限公司 | Veterinary anti-IL 31 antibodies |
| WO2021154947A1 (en) * | 2020-01-28 | 2021-08-05 | Ubi Ip Holdings | Peptide immunogens targeting pcsk9 and formulations thereof for prevention and treatment of pcsk9-mediated disorders |
| AU2021383841A1 (en) * | 2020-11-23 | 2023-06-22 | Scout Bio, Inc. | Antigen-binding molecules and uses thereof |
| WO2023161526A1 (en) | 2022-02-28 | 2023-08-31 | Tridem Bioscience Gmbh & Co Kg | A CONJUGATE CONSISTING OF OR COMPRISING AT LEAST A ß-GLUCAN OR A MANNAN |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI229679B (en) * | 1998-06-20 | 2005-03-21 | United Biomedical Inc | Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens |
| US8790651B2 (en) * | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| US9102752B2 (en) * | 2013-03-15 | 2015-08-11 | United Biomedical, Inc. | Peptide vaccine for prevention and immunotherapy of dementia of the Alzheimer's type |
| MA40824A (en) * | 2014-10-22 | 2017-08-29 | Saiba Gmbh | MODIFIED VIRUS TYPE CMV PARTICLES |
| EP3302457A2 (en) | 2015-06-08 | 2018-04-11 | Lophius Biosciences GmbH | Composition for determination of cell-mediated immune responsiveness |
| WO2017042212A1 (en) * | 2015-09-08 | 2017-03-16 | Universität Zürich | Treatment of insect bite hypersensitivity |
| US10946078B2 (en) * | 2016-04-27 | 2021-03-16 | Benchmark Animal Health Ltd. | Treatment of canine atopic dermatitis |
-
2018
- 2018-12-11 WO PCT/US2018/065025 patent/WO2019118512A2/en unknown
- 2018-12-11 US US16/771,948 patent/US20210079054A1/en active Pending
- 2018-12-11 TW TW107144910A patent/TWI741241B/en active
- 2018-12-11 AU AU2018383708A patent/AU2018383708B2/en active Active
- 2018-12-11 SG SG11202005526WA patent/SG11202005526WA/en unknown
- 2018-12-11 JP JP2020550063A patent/JP7250032B2/en active Active
- 2018-12-11 EP EP18888645.1A patent/EP3724218A2/en not_active Withdrawn
- 2018-12-11 MX MX2020006105A patent/MX2020006105A/en unknown
- 2018-12-11 BR BR112020011308-5A patent/BR112020011308A2/en not_active IP Right Cessation
- 2018-12-11 CN CN201880079547.1A patent/CN111448208B/en active Active
- 2018-12-11 KR KR1020207020001A patent/KR20210009296A/en active IP Right Grant
- 2018-12-11 CA CA3085318A patent/CA3085318A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN111448208A (en) | 2020-07-24 |
| WO2019118512A3 (en) | 2020-04-09 |
| CN111448208B (en) | 2024-02-27 |
| JP7250032B2 (en) | 2023-03-31 |
| MX2020006105A (en) | 2020-11-09 |
| TW201927813A (en) | 2019-07-16 |
| RU2020122924A (en) | 2022-01-14 |
| EP3724218A2 (en) | 2020-10-21 |
| US20210079054A1 (en) | 2021-03-18 |
| TWI741241B (en) | 2021-10-01 |
| WO2019118512A2 (en) | 2019-06-20 |
| JP2021510169A (en) | 2021-04-15 |
| AU2018383708B2 (en) | 2023-10-26 |
| KR20210009296A (en) | 2021-01-26 |
| CA3085318A1 (en) | 2019-06-20 |
| BR112020011308A2 (en) | 2020-11-17 |
| AU2018383708A1 (en) | 2020-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL277648A (en) | Therapeutic microbiota for the treatment and/or prevention of food allergy | |
| IL268406A (en) | Compositions and methods for the treatment of hemoglobinopathies | |
| SG11202005526WA (en) | Peptide immunogens of il-31 and formulations thereof for the treatment and/or prevention of atopic dermatitis | |
| IL290150A (en) | Compositions and methods for the treatment of chronic pain | |
| ZA201905851B (en) | Peptides and methods for the treatment of diabetes | |
| SG10201402819WA (en) | Composition for prevention and treatment of joint pain and the method of preparation thereof | |
| IL263477A (en) | Compositions and methods for the treatment or prevention of oxalate-related disorders | |
| IL266486A (en) | Pharmaceutical compositions and methods for the treatment of cancer | |
| IL272121A (en) | Composition and methods for the treatment of myopia | |
| EP3518918A4 (en) | Methods and pharmaceutical compositions for the treatment of non-alcoholic steatohepatitis | |
| HK1257853A1 (en) | Compositions and methods for the treatment and prevention of radiation dermatitis | |
| EP3423064A4 (en) | Formulations of testosterone and methods of treatment therewith | |
| IL272097A (en) | Compounds for the prevention and treatment of medical disorders and uses thereof | |
| SG11201705524SA (en) | Compositions and methods for the treatment of inflammation and pain | |
| EP3468540A4 (en) | Pharmaceutical compositions and methods for treatment of pain | |
| HK1259125A1 (en) | Methods and formulations for treatment and/or prevention of blood-associated disorders | |
| EP3697387A4 (en) | Combination of as1411 and sapc-dops for the treatment of glioblastoma multiforme | |
| EP3518951A4 (en) | Compositions and methods for the treatment of orthopedic ailments | |
| EP3525787A4 (en) | Methods of treatment and pharmaceutical compositions using bcn057 or bcn512 | |
| IL272147A (en) | Methods and compositions for the treatment of cancer | |
| GB201614415D0 (en) | Enzymes for the treatment of human enterometabolic dysfunction | |
| IL265242B (en) | Compositions for the treatment of hypertension and/or fibrosis | |
| SG11202004005RA (en) | Pharmaceutical compositions for controlling and/or reducing the progression of myopia | |
| EP3131635A4 (en) | Compositions and methods for the treatment or prevention of neurodegenerative disorders | |
| HK1252359A1 (en) | Combination of trazodone and gabapentin for the treatment of pain |